Dezima Pharma, a Naarden, The Netherlands-based biotechnology company developing innovative drugs to treat dyslipidemic patients suffering from cardiovascular disease (CVD), will be acquired by Amgen, Inc. (NASDAQ: AMGN) for up to US$1.55bn.
Forbion Capital Partners, BioGeneration Ventures and New Science Ventures sold their shareholdings.
The transaction, subject to obtaining U.S. Federal Trade Commission clearance, include an upfront payment of US$300m, milestone payments of up to US$1.25bn and low-single-digit royalties on net product sales above a certain threshold.
Founded in 2012 by Prof. John Kastelein, Professor of Medicine at the Department of Vascular Medicine at the Academic Medical Center of the University of Amsterdam, The Netherlands, and led by Rob de Ree, CEO, Dezima develops TA-8995, an oral, once-daily CETP inhibitor in-licenced from Mitsubishi Tanabe Pharma Corporation.
Mitsubishi Tanabe Pharma will receive a portion of the upfront payment and future development and sales milestones from Dezima. Mitsubishi will also retain development and commercialization rights to TA-8995 in certain territories in Asia, including Japan.